Expensive biomedicine sets the agenda
The number of biological drugs under clinical development in Denmark has increased rapidly in later years, as have government expenses for biomedicine.
af LEONORA BECK
Biotech companies all over the world are focusing more and more on the development of biological drugs, rather than chemical ones, and the tendency is seen in Denmark as well.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
